Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Supernus Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus Pharmaceuticals offers portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson"s disease, ADHD, and depression.
Website: supernus.com


  • Bad financial results growth rate -8.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (20.1%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 9.6% (LTM)
  • Share price is 41.9% higher than minimum and 23.3% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (8.0x vs 19.1x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: SUPN
Share price, USD:  (+1.0%)32.23
year average price 33.15  


year start price 27.54 2024-06-05

min close price 25.77 2024-07-02

max close price 40.00 2025-02-04

current price 32.23 2025-06-04
Common stocks: 55 864 692

Dividend Yield:  0.0%
FCF Yield LTM: 9.6%
EV / LTM EBITDA: 8.0x
EV / EBITDA annualized: 13.1x
Last revenue growth (y/y):  +4.2%
Last growth of EBITDA (y/y):  -21.2%
Historical revenue growth:  +11.7%
Historical growth of EBITDA:  +28.6%
EV / Sales: 1.7x
Margin (EBITDA LTM / Revenue): 20.9%

Target EV / EBITDA (hist percentile): 19.1x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 801
Net Debt ($m): -437
EV (Enterprise Value): 1 364
EBITDA LTM (млн $): 170
EV / LTM EBITDA: 8.0x
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-14zacks.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

2025-05-06seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript

2025-05-06zacks.com

Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say

2025-05-06zacks.com

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates

2025-04-28zacks.com

What Makes Supernus (SUPN) a New Buy Stock

2025-04-21accessnewswire.com

Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN

2025-03-12accessnewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud

2025-03-04globenewswire.com

Supernus to Participate in Two Upcoming Investor Conferences

2025-02-28accessnewswire.com

Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN

2025-02-25zacks.com

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-04 2024-08-06 2024-05-08 2024-02-27 2023-11-08 2023-08-08 2023-05-09 2023-03-09 2022-11-09
acceptedDate 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 176M 168M 144M 164M 154M 136M 154M 167M 177M
costOfRevenue 38M 39M 37M 41M 20M 21M 23M 23M 26M
grossProfit 138M 130M 107M 123M 134M 114M 130M 144M 151M
grossProfitRatio 0.786 0.771 0.742 0.749 0.873 0.844 0.847 0.863 0.854
researchAndDevelopmentExpenses 29M 26M 24M 23M 23M 24M 21M 18M 20M
generalAndAdministrativeExpenses 15M 27M 27M 26M 26M 27M 28M 26M 27M
sellingAndMarketingExpenses 54M 59M 60M 55M 57M 60M 57M 48M 86M
sellingGeneralAndAdministrativeExpenses 70M 86M 87M 81M 83M 87M 86M 74M 112M
otherExpenses 0 16M 0 -20M 0 0 20M 21M 21M
operatingExpenses 117M 111M 111M 104M 127M 131M 127M 112M 153M
costAndExpenses 135M 150M 148M 145M 146M 152M 150M 135M 178M
interestIncome 4M 4M 3M 2M 2M 1M 5M 2M 3M
interestExpense 0 0 0 -5M 0 910 000 2M 2M 2M
depreciationAndAmortization 20M 21M 21M 43 812 22M 21M 20M 21M 21M
ebitda 65M 39M 17M 41M 31M 5M 29M 55M 22M
ebitdaratio 0.37 0.231 0.115 0.247 0.203 0.039 0.188 0.329 0.126
operatingIncome 41M 18M -4M 19M 8M -18M 9M 34M 2M
operatingIncomeRatio 0.232 0.108 -0.03 0.116 0.053 -0.13 0.058 0.205 0.01
totalOtherIncomeExpensesNet 4M 4M 4M -18M 456 000 -790 000 142 000 806 000 -2M
incomeBeforeTax 45M 26M 243 000 990 000 10M -17M 9M 35M -444 000
incomeBeforeTaxRatio 0.256 0.156 0.002 0.006 0.064 -0.126 0.059 0.21 -0.003
incomeTaxExpense 6M 6M 119 000 -185 000 26M -16M -8M 10M -2M
netIncome 38M 20M 124 000 1M -16M -831 000 17M 25M 2M
netIncomeRatio 0.219 0.118 0.001 0.007 -0.104 -0.006 0.11 0.152 0.01
eps 0.7 0.36 0.002 0.022 -0.29 -0.015 0.31 0.47 0.03
epsdiluted 0.69 0.36 0.002 0.021 -0.29 -0.015 0.29 0.43 0.03
weightedAverageShsOut 55M 55M 55M 55M 55M 55M 54M 54M 54M
weightedAverageShsOutDil 56M 56M 56M 55M 55M 55M 62M 62M 55M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-04 2024-08-06 2024-05-08 2024-02-27 2023-11-08 2023-08-08 2023-05-09 2023-03-09 2022-11-09
acceptedDate 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 32M 52M 63M 75M 95M 25M 58M 93M 111M
shortTermInvestments 372M 295M 234M 180M 105M 127M 170M 368M 280M
cashAndShortTermInvestments 403M 347M 298M 255M 200M 152M 229M 461M 392M
netReceivables 145M 152M 148M 144M 142M 137M 144M 165M 164M
inventory 64M 68M 75M 77M 83M 91M 91M 92M 83M
otherCurrentAssets 27M 23M 24M 17M 24M 45M 16M 16M 25M
totalCurrentAssets 640M 591M 544M 493M 449M 424M 883M 734M 664M
propertyPlantEquipmentNet 12M 40M 43M 43M 14M 14M 15M 15M 16M
goodwill 117M 117M 117M 117M 117M 117M 117M 117M 117M
intangibleAssets 540M 560M 580M 600M 641M 662M 682M 702M 723M
goodwillAndIntangibleAssets 657M 677M 697M 717M 758M 779M 800M 819M 840M
longTermInvestments 0 -11M 12M 17M 25M 37M 54M 94M 132M
taxAssets 7M 11M 20M 131M 35M 44M 50M 0 0
otherNonCurrentAssets 26M 8M -11M 9M 4M -6M -9M 40M 41M
totalNonCurrentAssets 703M 725M 760M 916M 836M 870M 908M 968M 1 029M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 1 343M 1 316M 1 304M 1 409M 1 285M 1 293M 1 792M 1 703M 1 693M
accountPayables 6M 5M 14M 2M 3M 4M 95M 96M 110M
shortTermDebt 9M 10M 9M 8M 8M 8M 481M 402M 401M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 1 229M 219M 0 50M 58M
otherCurrentLiabilities 276M 294M 291M 280M 47M 21M 155M 140M 156M
totalCurrentLiabilities 292M 309M 315M 290M 288M 253M 732M 688M 726M
longTermDebt 29M 30M 33M 33M 34M 34M 37M 36M 36M
deferredRevenueNonCurrent 0 -1 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 11M 20M 156M 35M 44M 50M 50M 58M
otherNonCurrentLiabilities 15M 8M 8M 8M 16M 42M 62M 43M -456M
totalNonCurrentLiabilities 44M 50M 60M 197M 85M 121M 148M 128M 114M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 38M 40M 33M 33M 42M 42M 37M 36M 36M
totalLiabilities 336M 358M 375M 487M 373M 373M 880M 816M 840M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 55 000 55 000 55 000 55 000 55 000 55 000 54 000 54 000 54 000
retainedEarnings 541M 503M 483M 483M 481M 497M 498M 481M 456M
accumulatedOtherComprehensiveIncomeLoss 78 000 -372 000 -534 000 -593 000 -1M -2M -2M -3M -4M
othertotalStockholdersEquity 466M 455M 447M 439M 432M 424M 416M 408M 401M
totalStockholdersEquity 1 007M 957M 929M 922M 912M 920M 912M 886M 853M
totalEquity 1 007M 957M 929M 922M 912M 920M 912M 886M 853M
totalLiabilitiesAndStockholdersEquity 1 343M 1 316M 1 304M 1 409M 1 285M 1 293M 1 792M 1 703M 1 693M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 343M 1 316M 1 304M 1 409M 1 285M 1 293M 1 792M 1 703M 1 693M
totalInvestments 372M 295M 246M 196M 130M 164M 224M 462M 412M
totalDebt 38M 40M 42M 42M 42M 42M 517M 438M 437M
netDebt 6M -12M -21M -34M -53M 17M 459M 345M 326M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-04 2024-08-06 2024-05-08 2024-02-27 2023-11-08 2023-08-08 2023-05-09 2023-03-09 2022-11-09
acceptedDate 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 38M 20M 124 000 1M -16M -831 000 17M 25M 2M
depreciationAndAmortization 20M 21M 21M 22M 22M 21M 21M 21M 22M
deferredIncomeTax -6M -8M -5M -10M -9M -6M -435 000 -8M -3M
stockBasedCompensation 8M 7M 6M 6M 8M 6M 6M 4M 5M
changeInWorkingCapital -8M -3M 14M 2M 30M -46M 5M -17M -24M
accountsReceivables 7M -5M -4M -2M -5M 4M 22M -1M -6M
inventory 5M 6M 2M 5M 7M -4M -2M -12M -8M
accountsPayables -12M -13M 10M -269 000 -6M -19M -11M -7M -24M
otherWorkingCapital -8M 9M 5M -395 000 34M -27M -10M 2M 14M
otherNonCashItems 2M 59M 42M 24M 2M 7M 288 000 2M 12M
netCashProvidedByOperatingActivities 54M 36M 38M 45M 36M -19M 49M 28M 14M
investmentsInPropertyPlantAndEquipment -200 000 -64 000 -248 000 36 000 -150 000 -159 000 -278 000 861 000 -147 000
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -225M -124M -194M -102M 0 0 0 -66M -134M
salesMaturitiesOfInvestments 148M 75M 142M 36M 35M 60M 240M 18M 52M
otherInvestingActivites 9000 -49M -51M 1 35M 0 0 -851 000 0
netCashUsedForInvestingActivites -77M -49M -52M -66M 35M 60M 240M -49M -82M
debtRepayment 0 0 0 -496M 0 -481M -15M 0 0
commonStockIssued 3M 2M 3M 3M -230 000 2M 2M 3M 6M
commonStockRepurchased 0 0 -1M -2M -230 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -387 000 -1000 -1M -2M 230 000 0 93M 0 0
netCashUsedProvidedByFinancingActivities 3M 2M 2M 1M -230 000 -479M 80M 3M 6M
effectOfForexChangesOnCash 0 0 0 -1 0 0 0 0 0
netChangeInCash -20M -11M -12M -20M 70M -437M 369M -18M -62M
cashAtEndOfPeriod 32M 52M 63M 75M 95M 25M 462M 93M 111M
cashAtBeginningOfPeriod 52M 63M 75M 95M 25M 462M 93M 111M 173M
operatingCashFlow 54M 36M 38M 45M 36M -19M 49M 28M 14M
capitalExpenditure -200 000 -64 000 -248 000 36 000 -150 000 -159 000 -278 000 861 000 -147 000
freeCashFlow 53M 36M 38M 45M 36M -19M 49M 28M 14M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-04 21:05 ET
Supernus Announces Third Quarter 2024 Financial Results
2024-10-31 20:10 ET
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
2024-10-17 20:05 ET
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
2024-10-10 21:12 ET
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
2024-09-24 11:30 ET
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
2024-09-19 20:30 ET
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
2024-08-28 20:15 ET
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
2024-08-19 11:00 ET
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
2024-08-06 20:06 ET
Supernus Announces Second Quarter 2024 Financial Results
2024-08-01 20:30 ET
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
2024-07-23 20:13 ET
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
2024-05-30 20:25 ET
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2024-05-23 20:05 ET
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
2024-05-09 20:05 ET
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
2024-05-08 20:05 ET
Supernus Announces First Quarter 2024 Financial Results
2024-05-07 14:00 ET
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
2024-05-01 12:00 ET
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
2024-04-24 20:05 ET
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
2024-04-08 12:00 ET
Supernus Provides Regulatory Update for SPN-830
2024-03-06 21:30 ET
Supernus to Participate in Two Upcoming Investor Conferences
2024-02-28 21:30 ET
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
2024-02-27 21:05 ET
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 21:05 ET
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
2024-02-05 13:30 ET
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
2023-12-19 12:30 ET
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
2023-11-08 21:05 ET
Supernus Announces Third Quarter 2023 Financial Results
2023-11-07 21:30 ET
Supernus to Participate in the Jefferies London Healthcare Conference
2023-11-02 11:00 ET
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
2023-10-25 20:15 ET
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
2023-10-16 21:34 ET
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
2023-10-09 20:45 ET
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
2023-09-27 20:15 ET
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
2023-09-10 00:00 ET
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
2023-08-31 21:30 ET
Supernus to Participate in the Wells Fargo Healthcare Conference
2023-08-21 13:00 ET
Bethany L. Sensenig Joins Supernus’ Board of Directors
2023-08-08 20:17 ET
Supernus Announces Second Quarter 2023 Financial Results
2023-07-24 20:05 ET
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
2023-05-31 20:15 ET
Supernus to Participate in the Jefferies Healthcare Conference
2023-05-09 20:05 ET
Supernus Announces First Quarter 2023 Financial Results
2023-05-02 20:05 ET
Supernus to Present at the Bank of America 2023 Health Care Conference
2023-04-25 20:15 ET
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
2023-04-03 20:05 ET
Supernus Announces Repayment of Convertible Notes
2023-03-08 21:05 ET
Supernus to Participate in Two Upcoming Investor Conferences
2023-03-01 21:55 ET
Supernus to Present at the Cowen 43rd Annual Health Care Conference
2023-02-28 21:05 ET
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
2023-02-14 21:30 ET
Supernus Enters Into $150 Million Credit Facility
2023-02-09 23:15 ET
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
2022-11-22 22:00 ET
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-08 22:30 ET
Supernus to Present at Two November Healthcare Conferences
2022-11-08 21:05 ET
Supernus Announces Third Quarter 2022 Financial Results
2022-10-25 20:30 ET
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
2022-10-10 12:30 ET
Supernus Provides Regulatory Update on SPN-830
2022-08-31 20:00 ET
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
2022-08-04 20:01 ET
Supernus Announces Second Quarter 2022 Financial Results
2022-07-25 21:00 ET
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
2022-06-02 20:05 ET
Supernus to Participate in the Jefferies Healthcare Conference
2022-05-09 20:05 ET
Supernus Announces First Quarter 2022 Financial Results
2022-05-02 20:55 ET
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
2022-05-02 12:30 ET
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
2022-04-30 00:00 ET
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
2022-04-13 20:11 ET
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
2022-04-04 21:00 ET
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
2022-03-17 12:30 ET
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
2022-03-02 13:00 ET
Supernus to Participate in Annual Cowen Health Care Conference
2022-02-28 21:05 ET
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
2022-02-22 21:30 ET
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
2022-02-22 13:00 ET
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
2021-12-08 13:30 ET
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
2021-11-24 23:58 ET
Supernus Pharmaceuticals Targeted in Ransomware Incident
2021-11-24 14:12 ET
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
2021-11-23 13:00 ET
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
2021-11-18 13:00 ET
Supernus to Participate in Annual Piper Sandler Healthcare Conference
2021-11-10 21:05 ET
Supernus to Participate in Upcoming November Investor Conferences
2021-11-03 20:01 ET
Supernus Announces Third Quarter 2021 Financial Results
2021-10-27 21:42 ET
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
2021-10-20 12:00 ET
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
2021-10-11 10:30 ET
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
2021-09-02 22:45 ET
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
2021-09-02 13:00 ET
Supernus to Participate in Upcoming September Investor Conferences
2021-08-04 20:09 ET
Supernus Announces Second Quarter 2021 Financial Results
2021-07-22 20:37 ET
Supernus to Host Second Quarter 2021 Financial Results Conference Call
2021-05-25 12:30 ET
Supernus to Present at Jefferies Virtual Healthcare Conference
2021-05-24 12:30 ET
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
2021-05-05 20:01 ET
Supernus Announces First Quarter 2021 Financial Results
2021-05-05 00:49 ET
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
2021-04-27 21:44 ET
Supernus to Host First Quarter 2021 Financial Results Conference Call
2021-04-02 20:58 ET
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
2021-02-26 14:00 ET
Supernus to Present at Cowen Healthcare Conference
2021-02-25 21:00 ET
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
2021-02-23 14:00 ET
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
2021-02-22 13:00 ET
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
2021-02-08 14:00 ET
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients  
2021-01-06 22:29 ET
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
2020-12-22 23:07 ET
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
2020-11-19 03:00 ET
Supernus to Participate in Annual Piper Sandler Healthcare Conference
2020-11-12 04:14 ET
Supernus to Present at Two November Investor Conferences
2020-11-09 23:30 ET
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
2020-11-03 21:30 ET
Supernus Announces Third Quarter 2020 Financial Results
2020-10-27 21:30 ET
Supernus to Host Third Quarter 2020 Financial Results Conference Call
2020-10-05 20:00 ET
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
2020-09-14 12:15 ET
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
2020-09-09 20:30 ET
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-02 20:30 ET
Supernus to Present at the Wells Fargo Virtual Health Care Conference
2020-08-18 22:06 ET
Supernus Announces Second Quarter 2020 Financial Results
2020-08-11 20:30 ET
Supernus Announces Preliminary Second Quarter 2020 Revenue
2020-06-26 22:29 ET
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
2020-06-09 19:46 ET
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
2020-05-27 20:30 ET
Supernus to Present at the Jefferies Virtual Health Care Conference
2020-05-15 20:15 ET
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®
2020-05-05 22:46 ET
Supernus Announces First Quarter 2020 Financial Results
2020-04-28 21:00 ET
Supernus to Acquire CNS Portfolio from US WorldMeds
2020-04-24 20:30 ET
Supernus to Host First Quarter Results Earnings Conference Call
2020-04-21 20:15 ET
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
2020-03-30 21:20 ET
Supernus Provides Business Update
2020-02-26 18:14 ET
Supernus to Present at the 2020 Cowen Health Care Conference
2020-02-25 21:40 ET
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
2020-02-11 21:05 ET
Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call
2020-01-21 23:33 ET
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
2020-01-08 15:30 ET
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference
2019-12-09 21:15 ET
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
2019-11-12 21:05 ET
Supernus to Present at Two November Healthcare Conferences
2019-11-11 21:15 ET
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
2019-11-05 21:55 ET
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
2019-10-24 20:10 ET
Supernus to Host Third Quarter 2019 Earnings Conference Call
2019-09-25 18:21 ET
Supernus to Present at the 2019 Cantor Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2025-05-06 20:20 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:14 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:14 ET
Supernus Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-23 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-23 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-25 00:00 ET
Supernus Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-04 16:19 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:13 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:13 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-21 00:00 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-21 00:00 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:18 ET
Supernus Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Supernus Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Supernus Pharmaceuticals reported for 2024 q1
SEC form 8
2024-04-24 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-24 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-27 16:15 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 16:15 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 16:14 ET
Supernus Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:14 ET
Supernus Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 16:10 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-25 00:00 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-08 16:29 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-08 16:19 ET
Supernus Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-24 16:08 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 8
2023-07-24 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-23 16:03 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-20 07:06 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-03 16:10 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 10
2023-03-09 16:15 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-02 16:19 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-01 17:01 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-28 17:03 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-14 17:03 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-10 00:00 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-09 18:19 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-09 17:07 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-08 17:09 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-25 16:34 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 8
2022-10-25 00:00 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-11 16:32 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-08 16:24 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 17:07 ET
Supernus Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-26 16:42 ET
Supernus Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-17 16:31 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-09 08:54 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 17:15 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-10 17:29 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-09 17:22 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 18:12 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:42 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-02 16:01 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-13 16:18 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 10
2022-04-13 16:06 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 10
2022-04-13 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-04-13 00:00 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-04 18:19 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-21 16:07 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 17:17 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 17:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:29 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:27 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:26 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:26 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:23 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:22 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:22 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-22 16:58 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-10 17:17 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-08 08:31 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 20:59 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 09:21 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 16:11 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 17:56 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-27 18:21 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-12 07:53 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-02 19:05 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-24 17:13 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-06 12:52 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-04 17:28 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:31 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-22 16:41 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:36 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-25 08:12 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-16 09:04 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-26 16:35 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-25 16:58 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-24 16:44 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-19 16:02 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-07 16:52 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 16:58 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 17:40 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 14:31 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-27 17:55 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-02 17:45 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-08 16:30 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-01 16:02 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-25 18:44 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 17:27 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 12:48 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:55 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:54 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:53 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:51 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:49 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:49 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:48 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:47 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:46 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:46 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-22 17:14 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-08 19:43 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-04 19:59 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-22 20:38 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-15 20:20 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-19 17:27 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-09 18:49 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 15:31 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-03 17:40 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-27 17:33 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-05 16:05 ET
Supernus Pharmaceuticals published news for 2020 q3